Clinical and Cost Effectiveness of a New Hepatocellular MRI Contrast Agent, Mangafodipir Trisodium, in the Preoperative Assessment of Liver Resectability

@article{Mann2001ClinicalAC,
  title={Clinical and Cost Effectiveness of a New Hepatocellular MRI Contrast Agent, Mangafodipir Trisodium, in the Preoperative Assessment of Liver Resectability},
  author={Gary N. Mann and Howard F. Marx and Lily Lau Lai and Lawrence David Wagman},
  journal={Annals of Surgical Oncology},
  year={2001},
  volume={8},
  pages={573-579}
}
Background: Improved preoperative assessment of focal liver disease and tumors could have a potentially significant impact on their treatment. Mangafodipir trisodium (Teslascan; Nycomed Amersham Imaging, Little Chalfont, UK) is a new hepatocellular contrast agent for use with state-of-the-art MR imaging that, in early reports, is accurate in detection and characterization of liver lesions. Methods: Records and diagnostic images of all patients undergoing enhanced Teslascan MRI (T-MRI) at our… CONTINUE READING